Improved Survival Outcome with Flat Dosing Pembrolizumab (Pembroxim®) in Late-Stage Non-Small Cell Lung Cancer- A Case Report

Historically, advanced and metastatic non-small cell lung cancer had dismal prognosis. These patients were subjected to best supportive care which included, inter alia, symptomatic management and advance care planning to get the best out of whatever time that is remaining for them. However, the past decade has seen important advances in treatment and diagnosis which have translated into improved survival outcomes in such cases. The Introduction of targeted therapy and immunotherapy for selected patients had dramatically changed the outcome of such patients, both in life expectancy and quality of life.